(Q38840236)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

review article

1 reference

title

Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

main subject

mesenchymal stem cell

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Daniele Noël

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Alexandre T J Maria

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Marie Maumus

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Alain Le Quellec

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Philippe Guilpain

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

publication date

1 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

Clinical Reviews in Allergy & Immunology

2 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

234-259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27207172%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12016-016-8552-9

2 April 2020

exact match

0 references

cites work

Human cord blood stem cells and the journey to a cure for type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Systemic sclerosis: An update in 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Update on mesenchymal stem cell-based therapy in lupus and scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Concise review: the surface markers and identity of human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Immunomodulatory properties of mesenchymal stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Native human adipose stromal cells: localization, morphology and phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Establishing criteria for human mesenchymal stem cell potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

MSC-based product characterization for clinical trials: an FDA perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells: biology and potential clinical uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Multipotent mesenchymal stromal cells and immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Engineering mesenchymal stem cells for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells: immune evasive, not immune privileged

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Soluble Tumor Necrosis Factor Receptor 1 Released by Skin-Derived Mesenchymal Stem Cells Is Critical for Inhibiting Th17 Cell Differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Interactions between human mesenchymal stem cells and natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human mesenchymal stem cells modulate B-cell functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Therapeutic potential of mesenchymal stem cells in regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell differentiation and roles in regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Formation of neurons by non-neural adult stem cells: potential mechanism implicates an artifact of growth in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

PLA-poloxamer/poloxamine copolymers for ligament tissue engineering: sound macromolecular design for degradable scaffolds and MSC differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Tissue engineering through autologous mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal stem cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

New PLGA-P188-PLGA matrix enhances TGF-β3 release from pharmacologically active microcarriers and promotes chondrogenesis of mesenchymal stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Inverse regulation of early and late chondrogenic differentiation by oxygen tension provides cues for stem cell-based cartilage tissue engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

A living thick nanofibrous implant bifunctionalized with active growth factor and stem cells for bone regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal cells condensation-inducible mesh scaffolds for cartilage tissue engineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells for the management of inflammation in osteoarthritis: state of the art and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Survival and biodistribution of xenogenic adipose mesenchymal stem cells is not affected by the degree of inflammation in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Multipotent mesenchymal stromal cells and the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Potential risks of bone marrow cell transplantation into infarcted hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells: flip side of the coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Sarcoma derived from cultured mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells reside in virtually all post-natal organs and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human adult stem cells from diverse origins: an overview from multiparametric immunophenotyping to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Comparison of multi-lineage cells from human adipose tissue and bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Phenotypic and functional heterogeneity of human bone marrow- and amnion-derived MSC subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stromal cells: misconceptions and evolving concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stromal cell characteristics vary depending on their origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Fat on sale: role of adipose-derived stem cells as anti-fibrosis agent in regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Adipose tissue-derived stem cells in clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Characterization of adipose tissue-derived cells isolated with the Celution system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Characterization of adipose-derived stem cells: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Identification of specific cell-surface markers of adipose-derived stem cells from subcutaneous and visceral fat depots

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Adipose Mesenchymal Stem Cells Isolated after Manual or Water-jet-Assisted Liposuction Display Similar Properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Evidence supporting antioxidant action of adipose-derived stem cells: protection of human dermal fibroblasts from oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The wound-healing and antioxidant effects of adipose-derived stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Unmet needs in the treatment of autoimmunity: from aspirin to stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Impaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Lupus nephritis: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Patterns of systemic lupus erythematosus expression in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cardiac involvement in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cardiovascular involvement in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Emerging and critical issues in the pathogenesis of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Tacrolimus use in lupus nephritis: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Systemic lupus erythematosus and atherosclerosis: Review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Treatment of refractory autoimmune diseases with ablative immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The efficacy of novel B cell biologics as the future of SLE treatment: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cell-based therapies for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Wnt/β-catenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53/p21 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Differential efficacy of human mesenchymal stem cells based on source of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory B cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Transplantation of Adipose Tissue-Derived Mesenchymal Stem Cells Prevents the Development of Lupus Dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Comparative Efficacies of Long-Term Serial Transplantation of Syngeneic, Allogeneic, Xenogeneic, or CTLA4Ig-Overproducing Xenogeneic Adipose Tissue-Derived Mesenchymal Stem Cells on Murine Systemic Lupus Erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell transplantation for diffuse alveolar hemorrhage in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Local transplantation of granulocyte colony-stimulating factor-mobilized human peripheral blood mononuclear cells for unhealing bone fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Tight control applied to the biological therapy of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Biologic therapies and systemic bone loss in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Clinical Observation of Employment of Umbilical Cord Derived Mesenchymal Stem Cell for Juvenile Idiopathic Arthritis Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Antineutrophil cytoplasmic antibody-associated renal vasculitis treated with autologous mesenchymal stromal cells: evaluation of the contribution of immune-mediated mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Insulin-Producing Cells Differentiated from Human Bone Marrow Mesenchymal Stem Cells In Vitro Ameliorate Streptozotocin-Induced Diabetic Hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Resveratrol augments therapeutic efficiency of mouse bone marrow mesenchymal stem cell-based therapy in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Intravenous administration of bone marrow mesenchymal stem cells benefits experimental autoimmune myasthenia gravis mice through an immunomodulatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Digestive tract involvement in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Fibrosis and immune dysregulation in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Systemic sclerosis refractory disease: from the skin to the heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Vascular complications of scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Pulmonary arterial hypertension in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

B cells in systemic sclerosis: a possible target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autoantibodies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Anti-topoisomerase I autoantibodies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Diagnosis and classification of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Quality of life in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The clinical relevance of sexual dysfunction in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Pulmonary complications: one of the most challenging complications of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Scleroderma renal crisis: a rare but severe complication of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Pulmonary hypertension in autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Genetic factors and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Immunogenetics of systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Cellular players in angiogenesis during the course of systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Angiogenic cytokines and growth factors in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Successes and failures of stem cell transplantation in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell treatments in rheumatology: a glass half full?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Expression of transforming growth factor β receptor II in mesenchymal stem cells from systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

New insights on chemically induced animal models of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Mesenchymal stem cell therapy in lung disorders: Pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Bone marrow-derived mesenchymal stem cells in repair of the injured lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The natural organosulfur compound dipropyltetrasulfide prevents HOCl-induced systemic sclerosis in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Propylthiouracil prevents cutaneous and pulmonary fibrosis in the reactive oxygen species murine model of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Simvastatin attenuates the development of pulmonary and cutaneous fibrosis in a murine model of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

The regenerative role of adipose-derived stem cells (ADSC) in plastic and reconstructive surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal stem cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

21 January 2018

Cell therapy of burns.

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Repeated autologous bone marrow-derived mesenchymal stem cell injections improve radiation-induced proctitis in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Therapeutic potential of gingival fibroblasts for cutaneous radiation syndrome: comparison to bone marrow-mesenchymal stem cell grafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-016-8552-9

Interstitial lung disease in systemic sclerosis

21 January 2018

1 reference

12 December 2020

Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6

1 reference

12 December 2020

Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period

1 reference

12 December 2020

Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use

1 reference

12 December 2020

Dose-dependent effects of intravenous allogeneic mesenchymal stem cells in the infarcted porcine heart

1 reference

12 December 2020

Alterations of ROS pathways in scleroderma begin at stem cell level.

1 reference

12 December 2020

Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis

1 reference

12 December 2020

Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients

1 reference

12 December 2020

Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression

1 reference

12 December 2020

Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience

1 reference

12 December 2020

Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

1 reference

12 December 2020

Skin fibroblasts are potent suppressors of inflammation in experimental arthritis

1 reference

12 December 2020

Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury

1 reference

12 December 2020

1 reference

12 December 2020

Induction of mesenchymal stem cell differentiation and cartilage formation by cross-linker-free collagen microspheres.

1 reference

12 December 2020

Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells

1 reference

12 December 2020

Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials

1 reference

12 December 2020

The Organotelluride Catalyst (PHTE)2NQ Prevents HOCl-Induced Systemic Sclerosis in Mouse

1 reference

12 December 2020

Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study

1 reference

12 December 2020

Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL Network

1 reference

12 December 2020

Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations

1 reference

12 December 2020

Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis

1 reference

12 December 2020

In vivo osteoprogenitor potency of human stromal cells from different tissues does not correlate with expression of POU5F1 or its pseudogenes

1 reference

12 December 2020

Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells

1 reference

12 December 2020

Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide

1 reference

12 December 2020

Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease

1 reference

12 December 2020

The role of pharmacologically active microcarriers releasing TGF-beta3 in cartilage formation in vivo by mesenchymal stem cells

1 reference

12 December 2020

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals

1 reference

12 December 2020

Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

1 reference

12 December 2020

Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus

1 reference

12 December 2020

Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L

1 reference

12 December 2020

Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus

1 reference

12 December 2020

Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus

1 reference

12 December 2020

Bone marrow endothelial progenitors are defective in systemic sclerosis

1 reference

12 December 2020

Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice

1 reference

12 December 2020

Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells

1 reference

12 December 2020

Human mesenchymal stem cells reduce lung injury in immunocompromised mice but not in immunocompetent mice

1 reference

12 December 2020

Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy

1 reference

12 December 2020

Fibroblast precursors in normal and irradiated mouse hematopoietic organs

1 reference

12 December 2020

Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells

1 reference

12 December 2020

Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation

1 reference

12 December 2020

Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients

1 reference

12 December 2020

Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells

1 reference

12 December 2020

Glucocorticoid-Induced Leucine Zipper Governs the Therapeutic Potential of Mesenchymal Stem Cells by Inducing a Switch From Pathogenic to Regulatory Th17 Cells in a Mouse Model of Collagen-Induced Arthritis

1 reference

12 December 2020

Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells

1 reference

12 December 2020

Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis

1 reference

12 December 2020

The immunosuppressive signature of menstrual blood mesenchymal stem cells entails opposite effects on experimental arthritis and graft versus host diseases

1 reference

12 December 2020

Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease

1 reference

12 December 2020

Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation

1 reference

12 December 2020

Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase

1 reference

12 December 2020